# Monoclonal Antibodies-Anti-IL/Anti-IgE

This is a subcategory of Respiratory Agents.

## Formulary

### Preferred

| Preferred  | Generic Name | Quantity | Time (Days) |
| :--------- | :----------- | :------: | :---------: |
| Fasenra <sup>PA</sup> |              |          |             |
| Dupixent <sup>PA</sup>    |              |          |             |
| Xolair <sup>PA</sup>  |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Nucala   |              |          |             |
| Tezspire      |              |          |             |

## Length of Authorizations

Initial: 180 days; Subsequent: 365 days

**All Authorizations**

Must be prescribed in accordance with FDA approved labeling

## Additional Criteria

### Clinical PA

-   Must be prescribed by or in consultation with an applicable specialist (i.e., allergist/immunologist, pulmonologist, or otolaryngologist)
-   For **Asthma** – Must have had uncontrolled asthma symptoms and/or exacerbations despite at least **30 days** with:
    -   Medium dose preferred ICS/LABA inhaler for 6 years and older **OR** medium dose preferred ICS/LABA inhaler with tiotropium or high dose ICS/LABA inhaler if 12 years and older
-   For **Chronic Rhinosinusitis with Nasal Polyposis** – Must have had an inadequate clinical response of at least **30 days** to at least **one oral** corticosteroid AND **one nasal** corticosteroid spray
-   For **Chronic Urticaria** – Must have had an inadequate clinical response to at least **14 days** with at least **two different** antihistamines

### Non-Preferred

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **90 days** with at least **one preferred** drug
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics, requests must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Links


[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=97)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=31)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
